Restoring Health, One Innovation at a Time

Our team is actively engaged in the development of a vaccine of the herpes simplex virus (HSV). This virus is a prevalent sexually transmitted infection known to induce genital sores, blisters, and ulcers. Our company's vaccine is founded upon an innovative methodology employing a modified iteration of the HSV virus. This approach is designed to stimulate a comprehensive immune response, offering promising prospects in combating HSV infections.

Excell Bio is preparing for testing in the development of an innovative cancer treatment that aims to rejuvenate the activity of the p53 gene. This gene, a pivotal tumor suppressor, orchestrates the self-destruction of cancerous cells. Unfortunately, mutations in the p53 gene afflict over 60% of human cancers. Employing cutting-edge methodologies, Exell Bio's treatment is intricately designed to reinvigorate the functionality of the p53 gene within cancer cells, resulting in their eradication and presenting a promising frontier in cancer therapeutics. 

Our team of genetic engineers works on developing gene therapies for a variety of genetic diseases. We use CRISPR/Cas9 technology and other cutting-edge techniques to create therapies that have the potential to cure genetic diseases.